We are upgrading Alkermes, Plc (ALKS) to Outperform following the impressive results delivered by the company in the final quarter of fiscal 2012 (the second full quarter following its merger with EDT). Alkermes beat the Zacks Consensus Estimate both in terms of revenues as well as earnings. Results were boosted by the inclusion of drugs belonging to the EDT unit of Elan.
The expanded portfolio caused the company to provide bright revenue guidance for fiscal 2013. We believe that Alkermes will achieve the guidance. We are also impressed by the FDA approval and launch of diabetes drug, Bydureon, which offers significant commercial potential.
We are also pleased by the pipeline progress at Alkermes. We believe that there is significant scope for stock price appreciation from current levels.
